ProfileGDS5678 / 1418192_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 93% 93% 92% 91% 93% 93% 96% 94% 93% 93% 93% 93% 94% 92% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.8496593
GSM967853U87-EV human glioblastoma xenograft - Control 27.9181993
GSM967854U87-EV human glioblastoma xenograft - Control 37.7557992
GSM967855U87-EV human glioblastoma xenograft - Control 47.6315691
GSM967856U87-EV human glioblastoma xenograft - Control 57.9583993
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.6800593
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 28.4686796
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 38.1374294
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.9483693
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.7872793
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.89893
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.920293
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 48.0275194
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.7159892